|Dr. Giovanni Caforio M.D.||Chairman and Chief Exec. Officer||5.11M||3.17M||52|
|Mr. Charles A. Bancroft||Chief Financial Officer, Head of Global Bus. Operations and Exec. VP||2.85M||N/A||57|
|Dr. Thomas J. Lynch Jr., M.D.||Chief Scientific Officer and Exec. VP||152.5k||N/A||56|
|Ms. Sandra Leung||Exec. VP and Gen. Counsel||2.45M||5.17M||56|
|Mr. Murdo Gordon||Chief Commercial Officer and Exec. VP||1.85M||N/A||N/A|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The companys products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreement with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb Company’s ISS Governance QualityScore as of May 1, 2017 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 4; Compensation: 6.